MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 255 filers reported holding MYRIAD GENETICS INC in Q2 2016. The put-call ratio across all filers is 3.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $31,651,924 | -32.1% | 1,973,312 | -1.8% | 0.75% | -28.4% |
Q2 2023 | $46,587,210 | -4.0% | 2,009,802 | -3.8% | 1.05% | -15.6% |
Q1 2023 | $48,522,452 | +47.2% | 2,088,784 | -8.1% | 1.24% | +47.3% |
Q4 2022 | $32,973,162 | -24.2% | 2,272,444 | -0.3% | 0.84% | -30.0% |
Q3 2022 | $43,474,000 | +25.9% | 2,278,490 | +19.9% | 1.21% | +29.9% |
Q2 2022 | $34,537,000 | -26.9% | 1,900,787 | +1.4% | 0.93% | -9.4% |
Q1 2022 | $47,237,000 | -7.3% | 1,874,478 | +1.5% | 1.02% | -0.1% |
Q4 2021 | $50,963,000 | -16.3% | 1,846,490 | -2.0% | 1.03% | -15.0% |
Q3 2021 | $60,868,000 | +5.9% | 1,885,032 | +0.3% | 1.21% | +10.0% |
Q2 2021 | $57,454,000 | +3.2% | 1,878,821 | +2.8% | 1.10% | -2.7% |
Q1 2021 | $55,667,000 | +35.5% | 1,828,131 | -12.0% | 1.13% | +42.2% |
Q4 2020 | $41,094,000 | +47.7% | 2,078,075 | -2.6% | 0.79% | +21.8% |
Q3 2020 | $27,826,000 | +11.8% | 2,133,877 | -2.7% | 0.65% | +8.0% |
Q2 2020 | $24,882,000 | -42.6% | 2,194,204 | -27.6% | 0.60% | -39.1% |
Q1 2020 | $43,350,000 | -44.3% | 3,029,345 | +6.0% | 0.99% | -22.8% |
Q4 2019 | $77,824,000 | -2.3% | 2,858,015 | +2.7% | 1.28% | -13.0% |
Q3 2019 | $79,649,000 | +5.9% | 2,782,027 | +2.8% | 1.47% | +5.4% |
Q2 2019 | $75,211,000 | -20.6% | 2,707,364 | -5.1% | 1.40% | -15.7% |
Q1 2019 | $94,689,000 | +143.1% | 2,852,064 | +112.8% | 1.66% | +106.7% |
Q4 2018 | $38,958,000 | -37.6% | 1,340,133 | -1.3% | 0.80% | -23.2% |
Q3 2018 | $62,438,000 | +28.4% | 1,357,351 | +4.3% | 1.05% | +16.5% |
Q2 2018 | $48,638,000 | +24.6% | 1,301,525 | -1.5% | 0.90% | +17.1% |
Q1 2018 | $39,041,000 | -15.7% | 1,321,171 | -2.0% | 0.77% | -15.9% |
Q4 2017 | $46,291,000 | -5.1% | 1,347,828 | -0.0% | 0.91% | -10.8% |
Q3 2017 | $48,775,000 | +38.6% | 1,348,107 | -1.0% | 1.02% | +39.2% |
Q2 2017 | $35,182,000 | +34.8% | 1,361,532 | +0.2% | 0.73% | +26.3% |
Q1 2017 | $26,097,000 | +14.4% | 1,359,197 | -0.7% | 0.58% | +11.5% |
Q4 2016 | $22,815,000 | -18.0% | 1,368,635 | +1.2% | 0.52% | -21.2% |
Q3 2016 | $27,832,000 | -33.0% | 1,352,357 | -0.4% | 0.66% | -36.7% |
Q2 2016 | $41,530,000 | -15.9% | 1,357,182 | +2.9% | 1.04% | -16.9% |
Q1 2016 | $49,388,000 | -15.2% | 1,319,482 | -2.2% | 1.26% | -14.3% |
Q4 2015 | $58,215,000 | +12.6% | 1,348,807 | -2.2% | 1.47% | +10.7% |
Q3 2015 | $51,682,000 | +11.5% | 1,378,932 | +1.2% | 1.32% | +18.3% |
Q2 2015 | $46,336,000 | -3.4% | 1,363,232 | +0.6% | 1.12% | -0.9% |
Q1 2015 | $47,957,000 | +63.5% | 1,354,707 | +57.3% | 1.13% | +62.0% |
Q4 2014 | $29,340,000 | -12.3% | 861,407 | -0.7% | 0.70% | -18.9% |
Q3 2014 | $33,453,000 | +2.3% | 867,332 | +3.2% | 0.86% | +0.6% |
Q2 2014 | $32,706,000 | +10.4% | 840,332 | -3.0% | 0.85% | +13.4% |
Q1 2014 | $29,626,000 | +70.5% | 866,512 | +4.6% | 0.75% | +66.2% |
Q4 2013 | $17,372,000 | -7.0% | 828,037 | +4.2% | 0.45% | -16.9% |
Q3 2013 | $18,680,000 | -10.2% | 794,880 | +2.6% | 0.54% | -19.0% |
Q2 2013 | $20,811,000 | – | 774,520 | – | 0.67% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |